自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.06.030

摘要/Abstract

摘要： 目的探讨自体骨髓干细胞(BMSC)经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者的疗效。方法 2015年1月～2020年1月我院收治的失代偿期乙型肝炎肝硬化患者76例,给予所有患者内科综合治疗,研究组在内科综合治疗的基础上进行自体BMSC经肝动脉肝内移植治疗。结果在治疗24 w末,研究组血清总胆红素水平为(17.2±2.3)μmol/L,显著低于对照组【(21.7±2.9)μmol/L,P<0.05】,血清白蛋白和血清前白蛋白水平分别为(31.4±5.8)g/L和(241.4±54.3)mg/l,显著高于对照组【(28.9±5.2)g/L和(197.8±42.7)mg/l,P<0.05】;研究组血清透明质酸、Ⅲ型前胶原和Ⅳ型胶原水平分别为(116.1±42.7)μg/L、(67.1±18.1)μg/L和(92.2±14.9)g/L,显著低于对照组【(163.5±38.8)μg/L、(98.7±21.3)μg/L和(112.8±16.7)g/L,P<0.05】;研究组外周血CD3⁺和CD4⁺细胞百分比及CD4⁺/CD8⁺比值分别为(67.2±4.3)%、(42.8±1.2)%和(1.5±0.1),显著高于对照组【(60.8±3.3)%、(37.6±4.6)%和(1.4±0.1),P<0.05】;研究组Child-Pugh评分为(7.8±1.7)分,显著低于对照组【(8.8±2.3)分,P<0.05】,MELD评分为(14.3±2.8)分,显著高于对照组【(17.6±2.4)分,P<0.05】。结论采用自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者可有效改善肝功能,安全,值得临床进一步验证。

关键词: 肝硬化, 自体骨髓干细胞, 经肝动脉肝内移植, 治疗

Abstract: Objective The aim of this study was to explore the efficacy of transarterial intrahepatic transplantation of autologous bone marrow stem cells (BMSCs) in the treatment of patients with decompensated hepatitis B-induced liver cirrhosis (LC). Methods A total of 76 patients with decompensated hepatitis B-induced LC were enrolled in our hospital between January 2015 and January 2020, and 41 patients received transarterial intrahepatic transplantation of BMSCs and all patients were treated by comprehensive internal medical therapy. Results At the end of 24 week treatment, serum bilirubin level in patients receiving BMSC transplantation was (17.2±2.3)μmol/L, significantly lower than [(21.7±2.9)μmol/L, P<0.05], while serum albumin and prealbumin levels were (31.4±5.8)g/L and (241.4±54.3)mg/l, significantly higher than [(28.9±5.2)g/L and (197.8±42.7)mg/l, respectively, P<0.05] in the control; serum hyaluronic acid, type III procollagen and type IV collagen levels were (116.1±42.7)μg/L, (67.1±18.1)μg/L and (92.2±14.9)g/L, significantly lower than [(163.5±38.8)μg/L, (98.7±21.3)μg/L and (112.8±16.7)g/L, respectively, P<0.05] in the control; the percentages of peripheral blood CD3⁺ cells and CD4⁺ cells as well as the ratio of CD4⁺/CD8⁺ cells were (67.2±4.3)%, (42.8±1.2)% and (1.5±0.1), significantly higher than [(60.8±3.3)%, (37.6±4.6)% and (1.4±0.1), respectively, P<0.05] in the control; the Child-Pugh score was (7.8±1.7), and the model for end-stage liver disease (MELD) score was (14.3±2.8), both significantly lower than [(8.8±2.3) and (17.6±2.4), respectively, P<0.05] in the control. Conclusion Transarterial intrahepatic transplantation of autologous bone marrow stem cells could effectively and safely improve liver functions in patients with decompensated hepatitis B cirrhosis, which is worthy of further clinical verification.

Key words: Liver cirrhosis, Autologous bone marrow stem cells, Transarterial intrahepatic transplantation, Therapy

王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.

Wang Jing, Bi Ning, Fang Liang, et al. Efficacy of transarterial intrahepatic transplantation of autologous bone marrow stem cells in the treatment of patients with decompensated hepatitis B cirrhosis[J]. Journal of Practical Hepatology, 2021, 24(6): 887-890.

参考文献

[1] Wang Y, Li XY, Wu LL, et al. Dynamic prediction of liver cirrhosis risk in chronic hepatitis B patients using longitudinal clinical data. Eur J Gastroenterol Hepatol, 2020, 32(1):120-126.
[2] Agbim U, Asrani S K. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol, 2019, 13(4):361-374.
[3] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol, 2008, 48(2):335-352.
[4] Esmaeilzadeh A, Ommati H, Kooshyar MM, et al. Autologous bone marrow stem cell transplantation in liver cirrhosis after correcting nutritional anomalies, a controlled clinical study. Cell J, 2019, 21(3):268-273.
[5] Zhang Y, Li Y, Zhang L, et al. Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis. Stem Cell Res Ther, 2018, 9(1):59.
[6] Chen B, Pang L, Cao H, et al. Autologous stem cell transplantation for patients with viral hepatitis-induced liver cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2019, 31(10):1283-1291.
[7] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):389-400.
[8] Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, et al. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. Plos One, 2018, 13(4):e0194922.
[9] Lee J, Kim DG, Lee JY, et al. Impact of model for end-stage liver disease score based allocation system in Korea: A nation-wide study. Transplantation, 2019, 103(12):2515-2522.
[10] Rengasamy M,Singh G,Fakharuzi NA,et al. Transplantation of human bone marrow mesenchymal stromal cells reduces liver fibrosis more effectively than Wharton's jelly mesenchymal stromal cells. Stem Cell Res Ther, 2017, 8(1):143.
[11] Huang KC, Chuang MH, Lin ZS, et al. Transplantation with GXHPC1 for liver cirrhosis: Phase 1 trial. Cell Transplant, 2019, 28(30):096368971988488.
[12] Mabuchi Y,Matsuzaki Y. Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs.Int J Hematol,2016,103(2):138-144.
[13] 闫焕杰, 张淑芹, 赵文静. 自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭患者疗效初步研究. 实用肝脏病杂志, 2019, 22(1):81-84.
[14] Huimin T, Yafeng L, Tingting W, et al. Umbilical cord blood stem cells transplantation as an adjunctive treatment strategy for liver cirrhosis in Chinese population: a meta-analysis of effectiveness and safety. Ther Clin Risk Manag, 2018, 14:417-440.
[15] Xue R, Meng Q, Li J, et al. The assessment of multipotent cell transplantation in acute-on-chronic liver failure: a systematic review and meta-analysis. Transl Res, 2018, 200(1):65-80.
[16] Patel DA. Haploidentical stem cell transplantation with post-transplantation cyclophosphamide for aggressive lymphomas: how far have we come and where are we going? World J Oncol, 2019, 10(1):1-9.
[17] 曹会娟, 张绍全, 翁伟镇, 等. 自体骨髓干细胞治疗失代偿期乙型肝炎肝硬化患者疗效及长期安全性观察. 中华传染病杂志, 2017, 35(12):719-724.
[18] 方雪晴, 张骏飞, 宋海燕,等. 脐带间充质干细胞移植对失代偿期乙型肝炎肝硬化患者免疫功能和转归的影响. 中华肝脏病杂志, 2016, 24(12):907-910.
[19] Vasícek J,Shehata M,Schnabl S,et al. Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells. Biotechnol Prog, 2018, 34(5):1278-1289.
[20] Yu SH, Liu LJ, Lyu B, et al. Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9,TIMP-1,INF-gamma and TGF-beta. Cell Biochem Funct, 2015, 22(4):227-31.